Transcode Therapeutics Stock Analysis

Transcode Stock Analysis Notes

The company has price-to-book ratio of 0.74. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Transcode Therapeutics recorded a loss per share of 792.4. The entity had not issued any dividends in recent years. The firm had 1:28 split on the 15th of May 2025. TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. The company was incorporated in 2016 and is based in Boston, Massachusetts. Transcode Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. To find out more about Transcode Therapeutics contact Thomas MBA at 857-837-3099 or learn more at https://www.transcodetherapeutics.com.

Transcode Therapeutics Investment Alerts

Transcode Therapeutics Upcoming and Recent Events

Transcode Largest EPS Surprises

View All Earnings Estimates

Transcode Therapeutics Environmental, Social, and Governance (ESG) Scores

Transcode Stock Institutional Investors

Note, although Transcode Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Transcode Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.27 M.

Transcode Profitablity

Management Efficiency

Transcode Therapeutics has return on total asset (ROA) of (0.9484) % which means that it has lost $0.9484 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4299) %, meaning that it created substantial loss on money invested by shareholders. Transcode Therapeutics' management efficiency ratios could be used to measure how well Transcode Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 8.71 in 2025, whereas Return On Tangible Assets are likely to drop (2.41) in 2025. At this time, Transcode Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 287.2 K in 2025, whereas Total Assets are likely to drop slightly above 7 M in 2025.

Technical Drivers

As of the 16th of July 2025, Transcode Therapeutics has the Coefficient Of Variation of 8034.0, semi deviation of 8.02, and Risk Adjusted Performance of 0.0214. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Transcode Therapeutics, as well as the relationship between them.

Transcode Therapeutics Price Movement Analysis

Transcode Therapeutics Insider Trading Activities

Transcode Therapeutics Outstanding Bonds

Transcode Therapeutics Predictive Daily Indicators

Transcode Therapeutics Corporate Filings

Transcode Therapeutics Forecast Models

Transcode Therapeutics' time-series forecasting models are one of many Transcode Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Transcode Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Transcode Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Transcode shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Transcode Therapeutics. By using and applying Transcode Stock analysis, traders can create a robust methodology for identifying Transcode entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Transcode analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Transcode analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Transcode Therapeutics stock analysis indicators help investors evaluate how Transcode Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Transcode Therapeutics shares will generate the highest return on investment. By understating and applying Transcode Therapeutics stock analysis, traders can identify Transcode Therapeutics position entry and exit signals to maximize returns.

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.